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Predicting major mental illness: ethical and
practical considerations
Stephen M. Lawrie, Sue Fletcher-Watson, Heather C. Whalley and Andrew M. McIntosh
Summary
An increasing body of genetic and imaging research shows that
it is becoming possible to forecast the onset of major psychi-
atric disorders such as depression and schizophrenia before
people become ill with ever improving accuracy. Practical
issues such as the optimal combination of clinical and biological
variables are being addressed, but the application of predictive
algorithms to individuals or in routine clinical settings have yet
to be tested. The development of predictive methods in mental
health comes with substantial ethical questions, including
whether people wish to know their level of risk, as well as
individual and societal attitudes to the potential adverse effects
of data sharing, early diagnosis and treatment, which so far
have been largely ignored. Preliminary data suggests that at
least some people think predictive research is valuable and
would take part in such studies, and some would welcome
knowing the results. Future initiatives should systematically
assess opinions and attitudes in conjunction with scientific and
technical advances.
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One of the major limitations in the practice of psychiatry, and one of
the perennial causes of controversy about the nature and manage-
ment of mental disorder, is the general lack of diagnostic tests.
This has led to a research thrust towards identifying ‘biomarkers’ –
clinical, blood, imaging, cognitive or other measures that have the
ability to accurately forecast the onset of illness in individuals
without clinical disorder, or provide additional diagnostic or prog-
nostic information in those presenting to clinical care. Arguably,
most valuable of all would be a test that could predict treatment
response or the lack of it. Some progress has been made in early
and differential diagnostic approaches to dementia and the practice
of old age psychiatry already includes routine (early) diagnostic
work-ups. Some advances have been made in schizophrenia, with
glimpses of potential in depression.1 But the practical and ethical con-
siderations ofmaking early diagnoses in general adult psychiatry have
received at most brief consideration.2,3 This overview considers the
main issues and makes suggestions for researchers in the field.
Predictive testing – the state of the science
A systematic review of risk prediction models in psychiatry up until
2013 identified 12 reported models for major depression and 24 for
schizophrenia or other primary psychotic disorders, among 1 or 2
reports for other conditions.4 Almost all of these studies have
been limited by small sample sizes and a lack of independent data
test sets. Studies on depression have rarely included biological vari-
ables, although a few are now available.5
Most progress has been made in predicting broadly defined
‘psychosis’, usually defined as the presence of above-threshold delu-
sions, hallucinations or formal thought disorder. Several models
having suitably robust diagnostic parameters such as an ‘area
under the curve’ (AUC) of around 0.8 – the level at which screening
programmes tend to be considered for implementation. Note
however that the prevalence of a condition is a critical consideration
here, because as the prevalence falls, the false-positive rate inevitably
rises. Accordingly, screening for psychosis in the general population
is not desirable andmost of these studies have examined people with
subthreshold psychotic symptoms presenting to ‘clinical high risk’
research services. Although transition rates vary, the generally
observed rate of transition to ‘psychosis’ is 30–40% over 2–3 years
of follow-up. Across studies, subthreshold symptom severity,
poorer functioning and a family history of schizophrenia are con-
sistent clinical predictors of transition.6,7 Biological approaches
tend to have focused on neuroimaging indices, usually involving
complex machine learning analyses, some of which have since
been replicated and validated in independent samples,8 but these
clinical and neuroimaging research streams have largely progressed
in parallel. Indeed, the only study we are aware of which has system-
atically evaluated various combinations of clinical and biological
parameters, and validated the predictive algorithm across multiple
sites, reported no advantage of including imaging data.9
The recent and ongoing discovery of numerous genetic risk
factors for schizophrenia and depression has opened up additional
predictive possibilities that have yet to be incorporated into multi-
variate analyses.10 In schizophrenia, a genome-wide association
study (GWAS) of more than 100 000 case-participants and controls
identified 108 loci associated with schizophrenia. Calculating a
polygenic risk score (PRS) for schizophrenia based on whether indi-
viduals had the risk variant at each locus, multiplied by the odds
ratio for that locus, captured about 7% of the variance in disease
liability in independent populations. This translates into an odds
ratio elevated 8–20× when comparing the highest and lowest
decile groups, depending on population.11 It should be noted,
however, that PRSs are not as yet validated in culturally diverse
groups – although this is a priority for the Psychiatric Genomics
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Consortium (http://www.med.unc.edu/pgc/). Similarly, for depres-
sion, a recent GWAS in 135 458 case-participants and 344 901 con-
trols identified 44 independent and significant loci, and those in the
highest decile of PRS risk have an increased odds ratio of 2.5× of
depression.12 Increasing the numbers in GWASs has already and
will further increase the number of ‘hits’, the explained variance
and predictive power. Moreover, a PRS seems to add predictive
power to simply having a family history.13,14
Genetic and other biomarkers for diagnosis are not necessarily
the same as those for treatment response. Symptom severity and
early response are generally useful clinical guides but one hardly
needs complex analyses to use them in clinical practice.15
Pharmacogenomic studies have thus far proved disappointing,
although PRSs and epigenetic markers such as DNA methylation
show some promise.16 There are other candidate biomarkers for
treatment response in first-episode psychosis,17 but they have yet
to be examined in multivariate studies. More progress has been
made with predicting antidepressant response in depression
through, for example, neuroimaging of anterior cingulate cortex
activity18 and in particular with machine learning models of mul-
tiple data types.19 Still greater predictive power may accrue by iden-
tifying neurophysiological subtypes that differentially predict
response to different treatments.20
Practical and ethical issues to be addressed
Evidence-based medicine guidelines21 recommend four steps in
establishing a validated predictive tool and decision rules for use
in clinical practice: selecting variables, validation at a single site, val-
idation at different sites and establishing the impact on clinical prac-
tice. We now have at least proof of concept for the first three steps in
predicting ‘psychosis’. Further work along those lines is, however,
likely to be required for particular populations and needs to demon-
strate that the prediction tool can change clinician behaviour and
benefit patients. Several hurdles remain, however, to be negotiated,
as follows.
Optimising prediction across research centres
There are already several large consortia (for example PSYSCAN:
http://psyscan.eu and PRONIA http://www.pronia.eu) developing
enhanced multivariate depression and psychosis prediction tools.
Their general approach is to use machine learning to combine clin-
ical, behavioural, cognitive, imaging and genetic data from different
modalities to optimise predictive algorithms. These will be tested
against what clinical trial and natural treatment history data are
available. Harmonising and standardising clinical, behavioural
and cognitive test administration and scoring are complex but tract-
able concerns. Varying approaches to clinical management and bio-
logical measurement across geographical and linguistic boundaries
are less easily dealt with. Neuroimaging is particularly problematic
because quantitative magnetic resonance imaging data are exquis-
itely sensitive to variations in imaging hard- and software and
takes time to process. Genetic assays are largely consistent thanks
to the years of work of the Psychiatric Genomics Consortium in
aggregating data-sets11,12 but, like neuroimaging facilities, largely
concentrated in European and North American research centres.
Data sharing
The data sharing required to build large and representative data-
bases for such studies opens up technical issues, such as dealing
with different scanners, imaging sequences and data processing at
each site; legal and ethical issues about sharing data and the poten-
tial risks of identification; and, data management issues because of
the size of the data files.22 Whole-genome genotyping, when
linked to other information or data-sets, is a potential threat to ano-
nymity and skull and cortex renderings from magnetic resonance
imaging can also potentially identify individuals. The ENIGMA
consortium has dealt with these issues by getting each site to
analyse their own imaging and genetic data using common proto-
cols, pooling the results by meta-analysis, and has thereby produced
cutting edge insights into the impact of genetic variation on imaging
indices and authoritative estimates on the differences between
various psychiatric disorders and control samples.23 However,
aggregating data reduces the richness of individual-level data-sets
and can limit utility by obstructing the comparison of each partici-
pant to the predictive models.
Informed consent (for research)
The issue as to how much should be explained to people about the
risks of various medical procedures is a live and unresolved one.
Particular issues arise in the context of ‘psychosis’, if accompanied
by a lack of awareness of or being out of touch with reality, with
respect to the ability and/or competency to give informed
consent. Consent and other ethical issues need also to be considered
in particular populations, including patients with varying levels of
comorbidity, intellectual disabilities and different understandings
of mental illness and the meaning of genetic testing. Competency
is, however, an abstract concept without an agreed definition or
standardised assessment. Seeking consent from proxies, parents
and advocates brings autonomy and confidentiality limitations,
but is a potential solution in particular situations. Consent to data
sharing can arguably never be fully informed regarding all current
and potential future uses of data – giving rise to varying conceptions
as to what extent individual autonomy is respected or not by broad
research consent. Similar issues arise when analysing routine clin-
ical health systems treatment and outcome data. Many countries
are now adopting the acceptable compromise that fully anonymised
data can be fairly safely exploited if one presumes consent unless
people specifically ‘opt out’ of research using routinely collected
data-sets. Indeed, we are currently engaged in participatory research
with community stakeholders to study attitudes to routine sharing
of health data of different types (see: https://mhdss.ac.uk).
Additional safeguarding measures could include mandatory train-
ing for users of routine and linked data-sets (equivalent to Good
Clinical Practice for clinical trials) and consultation with a stake-
holder advisory group for each application of existing data to a
new clinical or research question. However, such measures are
not yet established.
Feasibility in clinical practice
Currently, mental health professionals in general adult psychiatry
do not routinely use standardised assessments, because of concerns
about their accuracy, utility and the time involved. It is, however,
desirable that the data we use in clinical practice and in research
is better harmonised. Routine collection of risk, treatment and
outcome data in clinical practice could be used to inform patients,
carers and health professionals about factors that could improve
prevention and treatment for mental disorders. Although clinicians
could probably be persuaded to adopt brief measurements if they
were shown to improve patient care and outcomes, this would
represent a substantial culture change. Further difficulties would
arise if biological assays were to be included, given that genetic
and imaging samples take time to process and communicate the
results. The very sensitivity of neuroimaging to mental state
means that it may both be among the strongest predictors but
least reliable measures if strict protocols are not followed, which is
not always possible in a busy clinical imaging environment, where
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planned sessions can be interrupted by the necessity of dealing with
medical emergencies. Not everyone is prepared to have, or able to lie
still for, a brain scan. Novel technologies such as portable neuroima-
ging devices may offer solutions here. In the meantime, PSYSCAN
and PRONIA researchers are allowing for these issues of limited
availability and technical complexity by building algorithms with
and without imaging. Neuroimaging may prove to be unnecessary
or prohibitively expensive; but patients may prefer imaging to cog-
nitive tests that they find more demanding24 and symptom and cog-
nitive assessments also share substantial variability.25 Multiple and
sequential testing may be both optimally predictive and necessary
for reliable clinical prediction,6 but raise logistical and financial
issues. Blood tests for diagnosis and treatment prediction are there-
fore generally preferable – not least in low- and middle-income
countries for example – but thus far none are available.
Communication of risks and benefits
One major issue that has hardly been addressed at all in research
studies to date is how to develop and return results that are mean-
ingful to individuals. After all, to render this technology suitable for
clinical use, there is a need to be able to make individual predictions.
Whereas a diagnostic test generates a binary outcome (disease
present or absent), prediction tools return probabilistic outcomes
(from 0% to 100% risk) that may have different implications for
interventions in particular people at various risk levels. Further,
these need to be available within a suitable time frame to be able
to influence clinical management. In addition, they should prefer-
ably be linked to one or more interventions that are known to
reduce the risk – even if that is, for example, brief interventions
seeking to reduce cannabis consumption and thereby the risk
of schizophrenia. Machine learning approaches, as currently
employed, are largely unsuited to delivering individual results
within short time frames. What is needed for clinical practice is
something more akin to a normal reference range for an individuals’
results to be compared with – similar to ‘N-of-1’ statistical testing26 –
and/or incorporated into a multivariate predictive model.
Diagnosis
One rarely remarked upon limitation of the ‘psychosis’ prediction
studies done to date is that most include a range of psychotic disor-
ders as part of the group of about one-third or so considered to have
become psychotic.7 But, a notable minority of these have brief or
transient psychoses that do not typically need ongoing treatment.
And others have for example delusional disorders that are often
treated, with some clinical trial justification, differently from schizo-
phrenia. There is also the consideration that about one-third of
those with an at-risk mental state will develop other non-psychotic
disorders. Similarly, depression can be transient and often spontan-
eously resolves within a year or so, but also has a tendency to recur.
Predictive testing studies therefore need to consider various diag-
nostic and therapeutic outcomes, including when no treatment is
desired or required.
Early detection ‘labelling’ and other potential adverse
effects
The stigma of mental illness seems to be slowly reducing in some
countries but remains a live concern. The contentious and often
shameful history of psychiatry lives long in folk memory.
Predictive testing, especially in general population screening
rather than those at risk presenting to services, may smack to
many of mind and behavioural control; and including genetics all
too readily stokesmemories of eugenics and fans fears of genetic dis-
crimination. A central concern about early detection and possible
intervention is that ‘labelling’ someone as at high risk may alter
how they, their parents, teachers and others in authority may act
towards them, and conceivably treat them in such a way as to
cause stress or promote behaviours that may actually increase
risk – and thereby even become a self-fulfilling prophecy. Equally,
however, communication of risk could alter behaviour for the
better, for example by improving diet or increasing physical activity,
such as has been observed in some studies in those at high polygenic
risk of heart disease.
Regardless, false positives and negatives are inevitable in any
screening/early diagnostic programme, and the risks of these need
to be balanced against the benefits for true positives and negatives.
The risks of false-positive (and early correct) diagnoses include:
potential consequences for employment and obtaining insurance,
adversely having an impact on relationships, other and self-
imposed restrictions and wider prejudice and discrimination. The
risks of false-negative (and delayed correct) diagnoses include:
exacerbating the condition through continued illicit drug use,
stress and delayed treatment. Some of these risks may be amelio-
rated by communicating levels of risk rather than dichotomies
(ideally accompanied by more widespread improvements in the
statistical and scientific literacy of the general population). Of
course, true positive results may benefit people through prompt
treatment and likely illness outcome improvements, whereas
people with true negatives might be reassured in the face of symp-
toms and/or a family history. But these are theoretical, somewhat
speculative observations. We simply do not know if and how indi-
viduals may be affected because, as far we are aware, they have yet to
be asked and the studies have yet to be done.
Early intervention
Above all, early detection research needs to be linked to therapeutic
initiatives, and demonstrate advantages for patients, delivering out-
comes that are endorsed by, and meaningful to, those affected.
These should ideally be demonstrated through clinical trials (but
such studies would be massive, very expensive undertakings). The
availability of different treatments and knowledge of their effective-
ness is likely to influence people’s attitudes to early diagnostic
testing and treatment. Indeed, desirable levels of the likely benefits
and risks of various interventionsmight well alter acceptable rates of
false-positive and false-negative diagnoses in different clinical scen-
arios. The AUC figures quoted above are balanced for sensitivity
and specificity because we have little information about which treat-
ments would be acceptable in different situations. Qualitative
studies and large population-based questionnaire surveys are there-
fore required in various at-risk populations to see at what level of
risk of depression or psychosis they might be prepared to take psy-
chotherapeutic, behavioural or pharmacological interventions with
known levels of beneficial and adverse effects. Further, demonstrat-
ing benefits to individuals taking part is an important influence on
participation in screening.
In the rest of medicine, the uptake rate of cervical, breast and
bowel cancer screening is encouraging, but that is for potentially
fatal diseases for which there are increasingly effective treatments.
Similarly, the routine use of cardiovascular disease risk reduction
treatment thresholds has been shown to save lives. As regards
neuropsychiatric disorders, Huntingtons chorea screening is
much less successful, but then there is of course no effective treat-
ment. For depression and psychosis, we do at least have good evi-
dence that a range of interventions are more or less equally
effective at improving outcomes in individuals with established
illness.27 Further, a systematic review of ten randomised clinical
trials has found that early intervention in psychosis reduces treat-
ment discontinuation, psychiatric hospital admissions and
Predicting major mental illness
3
symptom severity, and increases work involvement, over 6–24
months.28 Given, however, that psychotherapeutic approaches are
generally preferred by patients,29 non-pharmacological treatments
may be much more acceptable to those at high risk.
Attitudes to research and preventative practice
What do we know already about people’s attitudes to such studies and
their possible practical applications? A bit, but not much. During the
Edinburgh High Risk Study of schizophrenia,9,14 up until 2010, and as
part of the ongoing Bipolar Family Study,5 we held regular ‘data
parties’ to feedback the results to the participants. The vast majority
of those who were there and responded to surveys were supportive
of the search for predictive diagnostic tests (unpublished data). They
were of course, however, selected on the basis they were aged 18–25
at study outset, had at least two family members with schizophrenia,
or mood disorders and were participating in such research.
Using a social media (Facebook) based survey we collected
information in 2014 on general public opinions about pre-symp-
tomatic testing and treatment for schizophrenia. The final question-
naire was live for a 2-week period during which we received 385
responses (73% female) from young people predominantly in
their twenties. The majority of respondents (67%) indicated that
they would consider a pre-symptomatic brain scan if they were at
an increased risk of developing schizophrenia, 13% indicated that
would have a brain scan if they were at even the 1% population
risk, whereas 19% said that they would never have a brain scan.
Commonly voiced concerns included a potential waste of
National Health Service resources and time, that it could be a trau-
matic event and that population risk was not enough to warrant
screening. Most respondents (73%) stated that they would be pre-
pared to start pre-symptomatic treatment, but the threshold at
which they would take treatment varied widely, with more or less
equal numbers of people considering treatment across 0–100%
decile risk levels. This showed no apparent relationship with knowl-
edge about schizophrenia. Issues raised included insufficient evi-
dence of the efficacy of early diagnosis and treatment in reducing
the severity of the illness and potentially unnecessary exposure to
medication. At around 50% risk, most felt that the potential treat-
ment benefits – of keeping jobs, relationships and future plans –
outweighed potential adverse effects (unpublished data).
From 2011 to 2015we conducted an imaging and genetic study of
a large pedigree multiply affected with a structural genetic variant of
high penetrance and autosomal dominant like inheritance that
increases the risk ofmajor psychiatric disorders including depression,
bipolar disorder and schizophrenia to more than 50%.30 We found
ourselves in the somewhat contrary position, as dictated by ethics
committees, of having to discuss any neuroimaging abnormalities
with participants even if these were of no clinical relevance. On the
other hand, we were simultaneously obliged to not reveal their trans-
location status, despite its obvious clinical implications, unless people
specifically requested that we did. We found that the vast majority of
the younger generations of the family did not wish to know whether
or not they had the structural variant. This could reflect particular
concerns about structural variants (which are relatively rare but of
big effect, perhaps akin to Huntingtons chorea) and/or specific
issues that have an impact on this unique family.
Finally, this year, as part of a meeting about longitudinal cohort
studies concerned with mental health and illness in Scotland, we
surveyed a similar number but a much wider age range of partici-
pants. The vast majority of attendees were either definitely (50%)
or on balance (28%) prepared to have a research brain scan to
help predict later mental illnesses such as schizophrenia or depres-
sion. And very similar proportions indicated that they themselves
would definitely (47%) or on balance (26%) ‘have a brain scan
test of future mental illness, if it were safe and accurate’.
Conclusions
Early diagnosis and intervention in people at risk of developing
schizophrenia or depression is technically feasible and has the poten-
tial to improve patient outcomes and even prevent disorder. Indeed, it
is compatible with a public health, primary prevention approach. Risk
factors such as social adversity and illicit drug use could potentially be
mitigated, and have detectable epigenetic and other biological
effects.31 However, identifying those at elevated risk is not straightfor-
ward and some people will inevitably be mis-classified as likely to
become ill or not. There is therefore a need for further research to
optimise accuracy and utility. Moreover, as with any such prevention
strategy, there are important ethical considerations. Labelling
someone as ‘high risk’ for a major mental illness could have a sub-
stantial impact on their lives. The case is even more complex when
one considers the range of diagnoses and outcomes that are not in
the category of ‘major mental illness’, and if there is no consistent
and universally negative outcome to be avoided. Thus, definite
overall individual and, probably also, societal benefit needs to accrue.
The limited information we have available to us suggests a tan-
gible interest in early detection research and pre-symptomatic treat-
ment for schizophrenia in a sizeable majority of almost 1000 people
surveyed but found no clear risk level at which most people would
accept treatment. Thus, there appears to be an appetite for such
initiatives among both at-risk and general populations, but
researchers need to systematically assess opinions and attitudes
alongside technical advances. Key ethical considerations should be
part and parcel of these scientific investigations – such as, what is
it that people in these studies would want and are they typical of
clinical populations such as those in early-psychosis services?
A coordinated programme of work is required to translate
overall prediction profiles into individual risk scores, to find the
optimal combination of variables to enhance predictive power, to
test the acceptability of these approaches in relevant populations,
and then go on to demonstrate their practicality, impact and cost-
effectiveness. This is a rather full and daunting agenda but brings
with it the promise of improving the outcome of people with
some of the most severe psychiatric disorders as well as providing
objective diagnostic and therapeutic markers in psychiatry.
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